BioNTech (BNTX) CEO Sahin Ugur Sells 66,000 Shares

What Happened
Sahin Ugur, CEO of BioNTech SE (BNTX), sold a total of 66,000 ordinary shares in two open‑market transactions, disposing 34,000 shares at $98.26 ($3,340,809) on 2026‑09‑29 and 32,000 shares at $98.12 ($3,139,850) on 2026‑09‑30. The combined proceeds were approximately $6.48 million. These were sales (not purchases), which are often routine and do not by themselves indicate a change in company outlook.

Key Details

• Transaction dates & prices:
  • 2026‑09‑29: 34,000 shares sold at $98.26 — $3,340,809
  • 2026‑09‑30: 32,000 shares sold at $98.12 — $3,139,850
• Total shares sold: 66,000; total proceeds ≈ $6,480,659.
• Method: Open market sales executed pursuant to a Rule 10b5‑1 trading plan established by Mr. Ugur on June 3, 2026 (per filing remarks).
• Ownership post‑transaction: The Form 4 does not state a total "shares owned after" figure. The filing notes the shares are held by Medine GmbH (of which Mr. Ugur is the sole shareholder); 106,721 of the ordinary shares referenced are held in trust for an individual, and Mr. Ugur may be deemed to beneficially own Medine GmbH’s holdings (see footnote F1).
• Filing information: Form filed 2026‑09‑30 covering transactions on 2026‑09‑29 and 2026‑09‑30. This filing appears to be within the typical Form 4 reporting window (due within two business days of the transaction).

Context
These were planned sales under a preexisting 10b5‑1 plan, which is commonly used by insiders to sell shares on a predetermined schedule and reduces the implication that sales were based on material nonpublic information. Sales are routine insider activity; purchases generally carry more signal for bullish insider sentiment.